Jazz Pharmaceuticals — Press Release
FDA accepted sBLA with Priority Review and PDUFA date of August 25, 2026 for zanidatamab combinations in first-line HER2+ gastroesophageal adenocarcinoma. Priority Review designation suggests strong clinical data package. Watch for potential first-line expansion in competitive HER2+ space.